1,380 reports of this reaction
3.5% of all ERYTHROPOIETIN reports
#4 most reported adverse reaction
HAEMOGLOBIN DECREASED is the #4 most commonly reported adverse reaction for ERYTHROPOIETIN, manufactured by Janssen Products, LP. There are 1,380 FDA adverse event reports linking ERYTHROPOIETIN to HAEMOGLOBIN DECREASED. This represents approximately 3.5% of all 39,177 adverse event reports for this drug.
Patients taking ERYTHROPOIETIN who experience haemoglobin decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMOGLOBIN DECREASED is moderately reported among ERYTHROPOIETIN users, representing a notable but not dominant share of adverse events.
In addition to haemoglobin decreased, the following adverse reactions have been reported for ERYTHROPOIETIN:
The following drugs have also been linked to haemoglobin decreased in FDA adverse event reports:
HAEMOGLOBIN DECREASED has been reported as an adverse event in 1,380 FDA reports for ERYTHROPOIETIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMOGLOBIN DECREASED accounts for approximately 3.5% of all adverse event reports for ERYTHROPOIETIN, making it a notable side effect.
If you experience haemoglobin decreased while taking ERYTHROPOIETIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.